Table 1.

Demographic characteristics of all subjects combined and stratified by macular neovascularization (MNV) type

	Total (43 eyes)	Type 1 (26 eyes)	Type 2 (12 eyes)	Type 3 (5 eyes)	p
Mean age (95% CI), years	78 (76.14–80.46)	77.44 (74.38–80.5)	80 (76.25–83.75)	78.2 (73.59–82.81)	0.529
Sex, male/female	14/28	9/16	4/9	1/4	0.774
Mean follow-up (95% CI), years	2.09 (1.8–2.38)	2.01 (1.67–2.35)	2.49 (1.79–3.19)	1.55 (1.04–2.06)	0.276
Mean anti-VEGF injections (95% CI), n	10.58 (8.07–13.09)	10.31 (7.4–13.22)	10.93 (6.14–18.52)	8 (3.12–12.88)	0.754
Anti-VEGF agent, n
Aflibercept	18	12	5	1
Bevacizumab	7	5	1	1
Ranibizumab	5	1	2	2
Combination	14	7	6	1
Mean visual acuity, logMAR
Baseline	0.691	0.549	1.110	0.426	0.012*
Endpoint	0.733	0.620	1.147	0.329	0.006**

CI confidence interval

*p ≤ 0.05, **p ≤ 0.01